Lymphocyte depletion for kidney transplantation: Back to the past?

Nature Clinical Practice Nephrology

Volumn 4, Issue 10, 2008, Pages 534-535

  Cravedi, Paolo ^a   Mannon, Roslyn B ^b   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LYMPHOBLAST ANTIBODY; MONOCLONAL ANTIBODY; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADD ON THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; LYMPH NODE IRRADIATION; LYMPHOCYTE DEPLETION; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REPERFUSION INJURY; RISK BENEFIT ANALYSIS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION;

EID: 52949103613     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0914     Document Type: Short Survey

References (13)

1. Ciancio G et al. (2007) Induction therapy in renal transplantation: an overview of current developments. Drugs 67: 2667-2680
2. Noris M et al. (2007) Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 18: 1007-1018
3. Strober S et al. (1989) Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 321: 28-33
4. Segovia J et al. (2006) A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81: 1542-1548
5. Watson CJ et al. (2005) Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5: 1347-1353
6. Ciancio G and Burke GW 3rd (2008) Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 8: 15-20
7. Moxham VF et al. (2008) Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 180: 3910-3918
8. + regulatory T cells. J Am Soc Nephrol 17: 2844-2853
9. Bunnapradist S et al. (2007) Kidney transplant outcomes with alemtuzumab and thymoglobulin induction. American Society of Nephrology meeting [abstract #F-PO635]: 2007 October 31-November 5, San Francisco, CA, USA
10. Opelz G and Dohler B (2003) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4: 222-230
11. Ruggenenti P et al. (2006) Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 1: 546-554
12. + cells in vitro. Am J Transplant 5: 454-464
13. Ruggenenti P et al. (2007) Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 84: 956-964